Track record

With more than 70 combination products approved worldwide, SHL Medical has a proven track record of supporting pharmaceutical and biotech companies across all 12 IQVIA-recognized therapeutic areas.

A proven track record

SHL Medical is a trusted partner for pharmaceutical companies commercializing therapies across all therapeutic areas as defined by IQVIA. We work across both mature and emerging indications—from established autoimmune treatments to fast-growing areas like weight management—enabling successful market entry through robust, patient-centric device solutions designed for global scale. Since co-developing our first combination product in 1996, we have continuously advanced self-injection technologies, helping redefine the gold standard for the 21st century through bespoke and platform device offerings.

Get to know our products

0 1 2 3 4 5 6 7 8 9 0

Erectile Dysfunction

The launch of the PenInject 2.25 laid the foundation for SHL Medical’s journey, inspiring founder Roger Samuelsson’s vision of building a world‑leading self‑injection solutions company. The device was used to support the treatment of erectile dysfunction.

Erectile Dysfunction

In 2000, SHL Medical and its customer launched an updated version of the original 1996 product, building on early success and advancing its market reach.

Fertility Treatment

SHL Medical supported the manufacture of a pen injector for a customer marketing a fertility treatment indicated for both women and men, further solidifying its early expertise in pen‑based drug delivery.

Glaucoma

SHL Medical supported a customer in commercializing a specialized, patient‑focused mechanical aid designed to facilitate the administration of an eye‑drop therapy for glaucoma.

Anemia

SHL Medical’s DAI autoinjector was first brought to market alongside a therapy developed for the treatment of anemia associated with chronic kidney disease. As SHL Medical’s first widely commercialized autoinjector platform, DAI set the standard for self‑injection solutions until the introduction of the Molly platform.

Autoimmune and Inflammatory Diseases

SHL Medical delivered a breakthrough customer launch with the DAI autoinjector for a leading biologic therapy used to treat chronic inflammatory diseases. This pivotal collaboration accelerated the adoption of self‑injection for conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis, setting a new benchmark for the industry.

Autoimmune and Inflammatory Diseases

Following the landmark launch of DAI in 2006, the autoinjector was once again chosen to support a biologic therapy for chronic inflammatory diseases, this time enabling entry into a new geographic market and extending its international reach.

Aesthetics

SHL Medical supported a customer in launching a skin rejuvenation treatment using the Precision Pen Injector (PPI), a device designed for the precise delivery of hyaluronic acid, which also received the 2009 Red Dot Design Award.

Migraine

SHL Medical supported a customer in bringing a DAI autoinjector to market for the treatment of migraine and cluster headaches.

Hepatitis C

Working with a customer, SHL Medical helped bring a chronic hepatitis C treatment for both adult and pediatric patients into a self-injection format using the DAI autoinjector.

Multiple Sclerosis

SHL Medical supported a customer with a bespoke device for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis with relapses.

Multiple Sclerosis

In addition to developing a bespoke device for relapsing forms of multiple sclerosis, SHL Medical continued supporting the same customer with another device solution, further advancing drug delivery devices for multiple sclerosis patients.

Autoimmune and Inflammatory Diseases

SHL Medical supported a customer in commercializing a monoclonal antibody using the DAI autoinjector, expanding self‑injection treatment options for complex conditions such as rheumatoid arthritis and cytokine release syndrome.

Autoimmune and Inflammatory Diseases

The proven success of the DAI autoinjector enabled a previous biologic therapy for chronic inflammatory diseases to be commercialized again with a new partner, this time supporting expansion into an additional geographic market.

Anaphylaxis (Allergy)

SHL Medical supported a customer in the commercialization of an autoinjector designed for emergency anaphylaxis treatment.

Hepatitis C

SHL Medical supported a customer with a bespoke device which enabled the commercialization of a biologic for the treatment of hepatitis C.

Growth Hormone Deficiency

SHL Medical developed a bespoke device for a customer commercializing a biologic for daily injection therapy containing human growth hormone. Designed to support long‑term treatment, the device helps patients living with growth hormone-related disorders by enabling consistent dosing to support healthy bone and muscle development.

Multiple Sclerosis

SHL Medical supported a customer in launching an additional treatment for multiple sclerosis (MS) in an autoinjector format, further expanding self‑injection options within the MS therapy landscape.

Multiple Sclerosis

SHL Medical supported another customer in the commercialization of a therapy for multiple sclerosis, delivering a dedicated device solution to enable effective self‑administration.

Autoimmune and Inflammatory Diseases

SHL Medical supported a customer in commercializing an important therapy using an autoinjector across multiple markets, including China, marking the first SHL Medical autoinjector launched in the Chinese market. The device enables treatment for patients with moderate‑to‑severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non‑radiographic axial spondyloarthritis, and hidradenitis suppurativa.

Hypercholesterolemia (Lipid Lowering)

SHL Medical enabled the commercialization of a DAI-based combination product used to lower high blood cholesterol levels. The combination product is designed to reduce the risk of major cardiovascular events, including myocardial infarction, stroke, and unstable angina.

Hypercholesterolemia (Lipid Lowering)

SHL Medical supported a customer with the DAI autoinjector for a biologic therapy designed to address high blood cholesterol and support cardiovascular health, expanding treatment options for patients by targeting key risk factors associated with cardiovascular disease.

Growth Hormone Deficiency

SHL Medical supported a customer in commercializing a bespoke self‑injection solution for a synthetic human growth hormone therapy, enabling treatment of growth hormone deficiency in both pediatric and adult patients.

Autoimmune and Inflammatory Diseases

A significant milestone for SHL Medical was reached with the first commercial launch of a product using the Molly modular autoinjector platform. The device supported a customer therapy for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis, marking the platform’s transition from concept to commercial success.

Migraine

Momentum behind the Molly modular autoinjector platform continued in the same year with the launch of a customer product for the treatment of acute migraine.

Inflammatory Diseases

Building on the initial Molly launches, SHL Medical continued platform adoption in 2016 by supporting customers with the commercialization of an autoinjector for the inflammatory disease rheumatoid arthritis.

Multiple Sclerosis

SHL Medical supported a customer in commercializing a bespoke device solution for the treatment of multiple sclerosis, tailored to meet specific therapy and patient requirements.

Systemic Lupus Erythematosus

SHL Medical supported a customer in commercializing an autoinjector for the treatment of systemic lupus erythematosus and related autoimmune conditions, expanding self‑injection options for patients with complex chronic disease.

Autoimmune and Inflammatory Diseases

SHL Medical supported a customer in commercializing a device for an anti‑inflammatory therapy used to treat rheumatoid arthritis, enabling reliable self‑injection for long‑term disease management.

Autoimmune and Inflammatory Diseases

Working closely with a customer, SHL Medical supported the commercialization of an autoinjector for an anti‑inflammatory therapy targeting active polyarticular juvenile idiopathic arthritis, addressing the needs of children requiring long‑term treatment.

Multiple Sclerosis

SHL Medical supported a customer with a bespoke device-drug combination for multiple sclerosis, further strengthening its portfolio of customized solutions for complex neurological diseases.

Type 2 Diabetes

Together with AstraZeneca, SHL Medical developed an autoinjector for a once-weekly medication designed to improve blood sugar control in patients with type 2 diabetes. The device incorporates SHL Medical’s market-proven Needle Isolation Technology (NIT) and contains the drug in a pre-filled suspension formulation.

Migraine

Working with its longstanding pharma partner, SHL Medical leveraged its DAI platform for a combination product used in the prevention of migraines.

Autoimmune and Inflammatory Diseases

Leveraging the customizable Molly autoinjector platform, SHL Medical supported its pharma partner in launching a combination product for the treatment of autoimmune and inflammatory diseases, featuring a distinctive industrial design built on our proven platform technology.

Autoimmune and Inflammatory Diseases

In 2018, SHL Medical helped its customer launch a biosimilar of a prominent monoclonal antibody used in the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis. This combination product became one of the earliest biosimilars to launch with an autoinjector format.

Autoimmune and Inflammatory Diseases

SHL Medical supported its pharma partners in launching a biosimilar for autoimmune and inflammatory conditions such as rheumatoid arthritis. Developed through cross-continental collaboration with two pharmaceutical companies, the combination product helped set a precedent for biosimilar adoption in Europe.

Autoimmune and Inflammatory Diseases

Building on its longstanding relationship with its pharma partner, SHL Medical facilitated the launch of a biosimilar in an autoinjector format for the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis. This combination product played a key role in expanding patient access to biosimilars in the US.

Autoimmune and Inflammatory Diseases

SHL Medical supported its pharma partner by developing a customized device platform based on SHL Medical’s DAI technology. The combination product contains a monoclonal antibody used in the treatment of autoimmune and inflammatory diseases.

Autoimmune and Inflammatory Diseases

In 2019, SHL Medical collaborated with its pharma partner in launching a biosimilar combination product for the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis. This combination product leverages SHL Medical’s Molly autoinjector platform.

Severe Hypoglycemia

SHL Medical collaborated with its pharma partner to launch an autoinjector combination product for the treatment of severe or emergency hypoglycemia in patients with diabetes. Leveraging its Molly autoinjector platform, the combination product features a simple, easy-to-use design that enables safe and effective self-injection.

Autoimmune and Inflammatory Diseases

In 2019, SHL Medical collaborated with a pharma partner headquartered in Asia to launch an autoinjector combination product for the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis. The combination product leverages SHL Medical’s Molly autoinjector platform.

Postmenopausal Osteoporosis

Leveraging the DAI autoinjector platform, SHL Medical collaborated with its pharma partner to launch a combination product for the treatment of postmenopausal osteoporosis. The combination product features a distinctive industrial design built on our proven platform technology.

Autoimmune and Inflammatory Diseases

SHL Medical supported its pharma partner by developing a customized device platform for its biosimilar combination product used in the treatment of autoimmune and inflammatory diseases.

Hypercholesterolemia

SHL Medical led the lifecycle management of the device for a pharma partner’s combination product used to treat hypercholesterolemia. Leveraging SHL Medical’s customizable Molly platform, the product features a distinctive industrial design and color scheme tailored to the pharma partner’s portfolio of autoinjector combination products.

Atopic Disorders

In 2020, SHL Medical supported its pharma partner in launching the world’s first autoinjector with a 2.0 mL dose fill volume. The combination product, used for the treatment of atopic disorders, leverages SHL Medical’s Molly modular platform technology.

Ulcerative Colitis and Crohn’s Disease

Leveraging its Molly modular platform technology once again, SHL Medical supported one of its pharma partners in the development and launch of an autoinjector combination product used in the treatment of inflammatory bowel diseases.

Type 2 Diabetes

In 2020, SHL Medical supported its pharma customer in the development of an autoinjector combination product used in the treatment of type 2 diabetes. The combination product launched in Japan in three doses and leverages SHL Medical’s Molly modular platform technology.

Multiple Sclerosis

SHL Medical supported its customer in the development of a combination product used to treat relapsing forms of multiple sclerosis. Leveraging SHL Medical’s DAI autoinjector technology, the product features a distinctive industrial design tailored to the pharma partner’s portfolio of autoinjector combination products.

Severe Hypoglycemia

In 2021, SHL Medical supported the launch of a customer’s autoinjector combination product used to treat very low blood sugar levels in patients with diabetes. It leverages SHL Medical’s Molly modular platform technology.

Autoimmune and Inflammatory Diseases

Leveraging the customizable Molly autoinjector platform, SHL Medical collaborated with its pharma partner to launch a biosimilar combination product for the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis. The product features a distinctive industrial design built on our proven platform technology.

Weight Management

In 2021, SHL Medical supported one of the world’s leading pharma companies in launching an autoinjector combination product for weight management. The product features SHL Medical’s market-leading Molly autoinjector platform technology.

Osteoporosis

SHL Medical supported its pharma partner in launching a peptide-based combination product for the treatment of certain forms of osteoporosis, specifically by stimulating bone formation. This combination product leverages a pen solution developed by SHL Medical in the past – the Penny device.

Autoimmune and Inflammatory Diseases

In 2022, SHL Medical supported its pharma partner in launching a high-concentration version of its biosimilar combination product for the treatment of autoimmune and inflammatory conditions such as rheumatoid arthritis. Built on SHL Medical’s DAI platform, the product features an industrial design tailored to the pharma partner’s portfolio of autoinjector combination products.

Growth Hormone Deficiency

In 2022, SHL Medical led the lifecycle management of the device for a pharma partner’s combination product used to treat growth hormone deficiency and related growth disorders. The updated version leverages SHL Medical’s Madie pen technology and features a built-in dial, further enhancing usability and patient convenience.

Plaque Psoriasis

In 2023, SHL Medical supported its customer in the launch of an autoinjector combination product for the treatment of plaque psoriasis. This combination product leverages SHL Medical’s Molly modular platform technology.

Rheumatoid Arthritis

SHL Medical supported its pharma partner in launching a reformulated version of their combination product for the treatment of rheumatoid arthritis. This high-concentration biologic utilizes SHL Medical’s DAI platform and features an industrial design specifically tailored to the partner’s portfolio of autoinjector combination products.

Retinopathy of Prematurity

In 2023, SHL Medical facilitated the first in‑clinic dosing of Bayer’s biologic for the treatment of Retinopathy of Prematurity (ROP) using a novel device called Picleo®. This milestone was achieved through SHL Medical’s Micro Dosing Device (MDD) technology, which enables the precise administration of microliter volumes without disrupting established clinical workflows.

Prurigo Nodularis and Atopic Dermatitis

In 2024, SHL Medical supported the launch of a lyophilized biologic formulation for the treatment of prurigo nodularis and atopic dermatitis. The combination product utilizes SHL Medical’s Reunite autoinjector – a novel automatic reconstitution device that incorporates our market-proven NIT technology.

Plaque Psoriasis

SHL Medical once again collaborated with its pharma partner in the development of an autoinjector combination product for the treatment of plaque psoriasis. This high‑concentration dosing option leverages SHL Medical’s Molly modular platform technology and received regulatory approval in 2024.

Hemophilia A and B

In 2024, SHL Medical supported its pharma partner in the launch of an autoinjector combination product used to prevent or reduce bleeding episodes in people with severe hemophilia A or B. This was made possible through a bespoke platform device solution, specifically designed to cater to our partner’s portfolio of autoinjector combination products.

Rheumatoid Arthritis

In 2025, SHL Medical supported a leading Asia‑headquartered biopharmaceutical company in the launch of a biosimilar combination product for rheumatoid arthritis.

Rheumatoid Arthritis

SHL Medical supported the development and launch of an autoinjector combination product used in the acute treatment of migraine headaches (with or without aura) and acute cluster headaches in adults. This small-molecule drug leverages SHL Medical’s DAI autoinjector platform.

Plaque Psoriasis

In 2025, SHL Medical supported Sandoz in the launch of Pyzchiva® - the first ustekinumab biosimilar in Europe commercially available in an autoinjector. It leverages SHL Medical’s Molly modular platform autoinjector.

Asthma

SHL Medical supported the launch of two dosing formats for a biosimilar used in the treatment of allergic and inflammatory conditions, specifically asthma. These formats, which enable at-home injections, leverage SHL Medical’s Molly modular platform technology.

Autoinflammatory Diseases

In 2025, SHL Medical supported its pharma partner in the launch of an autoinjector combination product indicated for several rare autoinflammatory and systemic inflammatory conditions. The product leverages a customized device platform based on SHL Medical’s DAI technology and is designed to cater to the partner’s portfolio of autoinjector combination products.

Plaque Psoriasis

In 2026, SHL Medical supported a ustekinumab biosimilar using a Molly autoinjector.

Weight Management

Building on the successful 2021 launch, SHL Medical continued its collaboration with one of the world's leading pharmaceutical companies in 2026 to support the launch of a higher-dose autoinjector combination product for weight management. The product is based on SHL Medical's market-leading Molly autoinjector platform, demonstrating the platform's scalability and continued relevance in addressing growing patient needs.

2000

2001

2002

2005

2006

2009

2009

2011

2011

2012

2012

2013

2013

2013

2013

2013

2014

2015

2015

2015

2015

2015

2016

2016

2016

2016

2017

2017

2017

2017

2017

2018

2018

2018

2018

2018

2018

2019

2019

2019

2019

2020

2020

2020

2021

2021

2022

2022

2023

2023

2024

2025

2026

Back to start

Demonstrated across all therapeutic areas

From endocrine disorders to oncology and beyond, SHL Medical builds on this proven track record by partnering with leading pharmaceutical and biotech companies to bring combination products to market worldwide. Through patient‑centric, self‑administered solutions designed for real‑world use, we help expand access to care, support patient independence, and improve quality of life across a broad spectrum of therapeutic areas.

Endocrine and metabolic

Endocrine and metabolic diseases encompass a wide range of disorders that arise from hormonal imbalances or disruptions in the body’s metabolic processes, impacting everything from blood sugar regulation to bone health. SHL Medical has been at the forefront of delivering self-injection solutions for combination products used to treat conditions such as type 2 diabetes and hypercholesterolemia, as well as emerging treatments for weight management.

Musculoskeletal

Musculoskeletal diseases affect the bones, muscles, joints, and connective tissues, often leading to pain, disability, and a reduced quality of life. Treating and managing these diseases requires a comprehensive approach. Today, more than 20 of all the autoinjector combination products that SHL Medical helped develop are indicated for various musculoskeletal conditions, including one of the oldest blockbuster biologics indicated for rheumatoid arthritis and ankylosing spondylitis.

Dermatology

Dermatological diseases refer to a broad range of conditions affecting the skin, hair, and nails. These conditions vary widely in cause, severity, and symptoms, and can include infections, inflammatory disorders, autoimmune diseases, and skin cancers. Symptoms often involve changes in skin appearance, such as redness, rashes, scaling, itching, or abnormal pigmentation. In 2020, an autoinjector based on SHL Medical’s Molly platform was approved for the treatment of atopic disorders, setting a record as the world’s first 2.0 mL autoinjector combination product.

Cardiovascular

Cardiovascular diseases (CVDs) are among the leading causes of mortality globally. CVDs are a group of disorders affecting the heart and blood vessels, and these conditions are often caused by risk factors such as high blood pressure, high cholesterol, smoking, diabetes, obesity, and a sedentary lifestyle. Major types of CVDs include coronary artery disease, heart attack, heart failure, arrhythmias, and stroke. Since 2015, SHL Medical has supported the launch of six combination products indicated for cardiometabolic diseases and, in doing so, has supported the treatment journey of at least 1.6 million patients in this therapeutic area.

CNS

The central nervous system (CNS) is essential for life, serving as the main control center for processing and transmitting information throughout the body. CNS diseases encompass disorders that affect the brain and spinal cord, which are responsible for controlling body functions, movement, and cognition. Over the decades, SHL Medical has supported pharmaceutical companies in launching combination products for neurological conditions such as migraine, as well as for neurodegenerative disorders like multiple sclerosis.

Gastroenterology

Gastroenterological diseases are conditions that affect the gastrointestinal (GI) system, which includes the stomach, intestines, esophagus, liver, pancreas, and gallbladder. These diseases range from common disorders, such as acid reflux and gastritis, to more serious conditions like inflammatory bowel disease (IBD), liver disease, and colorectal cancer. Painful and often debilitating for sufferers, these conditions require biological treatments for effective management. SHL Medical has supported the launch of several combination products in this area, indicated for conditions such as ulcerative colitis and Crohn’s disease.

A doctor is examining a patient 's stomach in a hospital

Respiratory

Respiratory diseases are conditions that affect the lungs and airways, disrupting breathing and oxygen exchange. They include asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and lung cancer. Causes of respiratory diseases range from infections and environmental pollutants to smoking, genetic predisposition, and autoimmune reactions. Notably, the only biologic medicine globally approved for children with oral corticosteroid-dependent asthma utilizes SHL Medical's Molly autoinjector platform.

Genitourinary

Genitourinary diseases are conditions that affect the organs of the reproductive and urinary systems, including the kidneys, bladder, urethra, and reproductive organs. Common examples include urinary tract infections (UTIs), kidney stones, prostate disorders, incontinence, and cystitis. A combination product, first approved two decades ago for the treatment of anemia in patients with chronic kidney failure, leverages the DAI autoinjector developed by SHL Medical.

Oncology

According to the American Cancer Society, one in three people in the United States will be diagnosed with cancer during their lifetime. Oncology diseases, commonly referred to as cancers, encompass a broad range of conditions characterized by the uncontrolled growth and spread of abnormal cells in the body. These diseases can affect nearly any organ or tissue, leading to various types of cancer, including breast, lung, prostate, colorectal, and skin cancer. In this area, SHL Medical has supported the launch of a combination product indicated for chronic lymphocytic leukemia.

Ophthalmology

Ophthalmological diseases refer to a range of conditions that affect the eyes and visual system, leading to impaired vision or discomfort. Common examples include cataracts, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and conjunctivitis. In 2024, SHL Medical’s microdosing technology helped enable EYLEA® (aflibercept), delivered using the Picleo® paediatric dosing device, for the treatment of retinopathy of prematurity.

Infectious diseases

Infectious diseases are illnesses caused by pathogens, such as bacteria, viruses, fungi, or parasites, which invade the body and disrupt normal functions. These diseases can spread from person to person, through contaminated surfaces, or via vectors like insects. Effective prevention and treatment of infectious diseases often involve sanitation, vaccines, and antibiotic medications. To date, at least six combination products supported by SHL Medical's device technologies have been approved for treating various infectious diseases.